Stanley Frankel
Director/Board Member bij PRECISION BIOSCIENCES, INC.
Vermogen: 678 $ op 31-03-2024
Profiel
Stanley R.
Frankel is currently serving as an Independent Non-Executive Director at Precision BioSciences, Inc., Director at Myeloid Therapeutics, Inc., and Chief Medical Officer at Cytovia Therapeutics, Inc. Previously, he worked as SVP-Global Drug Development & Cellular Therapy at Bristol Myers Squibb Co. and VP, Head-Clinical R&D, Immuno-Oncology at Celgene Corp.
He holds a doctorate degree from Northwestern University and an undergraduate degree from Harvard College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-11-2023 | 50 ( 0.00% ) | 678 $ | 31-03-2024 |
Actieve functies van Stanley Frankel
| Bedrijven | Functie | Begin |
|---|---|---|
| PRECISION BIOSCIENCES, INC. | Director/Board Member | 12-04-2021 |
Cytovia Therapeutics, Inc.
 Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 01-04-2021 |
Myeloid Therapeutics, Inc.
 Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Director/Board Member | 30-06-2022 |
Eerdere bekende functies van Stanley Frankel
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-10-2020 |
| CELGENE | Chief Tech/Sci/R&D Officer | 01-11-2019 |
Opleiding van Stanley Frankel
| Northwestern University | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PRECISION BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Health Technology |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
